Skip to main content
. 2022 Jul 16;3:100119. doi: 10.1016/j.crphar.2022.100119

Table 3.

Indole-based MmpL3 inhibitors.

Sr. No. Compound Structure % Inhibition/IC50 Ref.
13. Indole-2-carboxamides Image 13 0.2 ​μg/ml (Franz et al., 2017)
14. N-cyclooctyl-6-trifluoromethylindol-2- ylmethylamine Image 14 0.13 ​μM (Tan et al., 2020)
15. N-(1-(adamantan-1-yl) ethyl)-4,6-dichloro-1H-indole-2- carboxamide Image 15 0.32 ​μM (Alsayed et al., 2021)
16. Adamantanol analogs Image 16 NA (Alsayed et al., 2021)
17. NITD-349, N-(4,4-dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide Image 17 NA (Yang et al., 2020)
18. Indolamide Image 18 >64 ​μg/mL (Lun et al., 2013)